# Regulatory Oversight & Global Rigor

In regulatory science, does the prevalence of FDA oversight on African trials indicate imported rigor from foreign regulatory frameworks rather than sovereign regulatory capacity? This audit evaluated regulatory oversight indicators for 23,873 African trials using ClinicalTrials.gov oversight module metadata through March 2026. An estimated thirty-one percent of African trials had FDA oversight designations, reflecting the dominance of internationally sponsored Phase 3 studies designed for United States regulatory submission. Africa's FDA oversight rate exceeded China's eighteen percent but fell below the United States domestic rate of seventy-two percent. Data monitoring committee rates were higher in African trials than in Chinese or Indian trials, again reflecting imported regulatory standards rather than local regulatory development. The 2,453 double-blind African trials (10% of total) demonstrated that imported regulatory standards enforce methodological rigour on the continent. These findings demonstrate that Africa's research quality is maintained by foreign regulatory frameworks. Interpretation is limited by voluntary disclosure of oversight arrangements.

## References

1. Alemayehu C, et al. "Behind the mask of the African clinical trials landscape." Trials. 2018;19:519.
2. Drain PK, et al. "Global migration of clinical trials." Nat Rev Drug Discov. 2018;17:765-766.

## Note Block

- Type: research
- App: https://mahmood726-cyber.github.io/africa-e156-students/governance-justice/dashboards/regulatory-oversight.html
- Code: https://github.com/mahmood726-cyber/africa-e156-students/blob/master/governance-justice/code/regulatory-oversight.py
- Data: ClinicalTrials.gov API v2
- Date: 2026-04-05